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Pioglitazone, a peroxisome proliferator activated receptor gamma (PPARg) agonist belonging to thiazo-
lidinedione class, is mainly used in diabetes mellitus. Obese subjects are twice likely to become
depressed than non-obese individuals. The biological mechanisms linking depression with obesity still
remain poorly understood and there is immense need for better therapeutic intervention against such
co-morbid disorders. The present study investigates the effect of pioglitazone on the chronic unpre-
dictable mild stress (CUMS) induced depression in obese mice by using behavioral tests and biochemical
estimations. Mice were fed with high fat diet (HFD) for 14 weeks and were further subjected to different
stress procedures for 28 days to induce depressive behavior. Animals were administered orally with
pioglitazone (30 mg/kg p.o.)/escitalopram (10 mg/kg p.o.)/vehicle (10 ml/kg p.o.) daily from day 15e28.
Various behavioral paradigms such as sucrose preference test, forced swim test (FST), tail suspension test
(TST) and elevated plus maze (EPM) were performed. Biochemical estimations including plasma glucose,
total cholesterol, triglycerides, and total proteins were performed. The data obtained from behavioral
assays and biochemical assessments indicated that obese animals exhibited severe depressive-like
behavior compared to non-obese animals. Furthermore, obese animals subjected to CUMS worsen the
depressive behavior compared to obese control animals. Repetitive treatment with pioglitazone reversed
the CUMS induced behavioral and biochemical alterations in HFD fed obese mice which atleast in part
may be mediated through improving altered plasma glucose. The study suggests that pioglitazone needs
further attention with respect to molecular mechanisms that could provide a better therapeutic strategy
against depression associated with obesity.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
National Comorbidity Survey reveals that major depressive
disorder (MDD) is a debilitating disease with a prevalence rate of
16.2% (Kessler et al., 2003). In depression remission is achieved by
only one third of the patients after treatment with antidepressant
agents (Rush et al., 2006). Another major disease as a global burden
is obesity as it is directly associated with increased morbidity from
cardiovascular disease, type 2 diabetes and some cancers. Epide-
miological data suggest that obesity is linked to an increased risk of
depressive and mood disorders (Simon et al., 2006). The current
antidepressants like citalopram and ﬂuoxetine have been reported
to show resistance in depression associated with obesity (IsingriniInc. This is an open access article uet al., 2010). Despite this information, there is presently little in-
formation on how the development of obesity heightens the risk
for depression.
Chronic unpredictable mild stress (CUMS) is the most important
pathogenic factor in several neuropsychiatric diseases such as
depressive disorder, as stress exposure modiﬁes the onset and
evolution of some neurological diseases (Garcia-Bueno et al., 2008).
In rodents, CUMS model is mostly used for assessing the patho-
physiology of depression and to study the effect of various thera-
peutic interventions on CUMS induced depression (Willner, 2005).
Furthermore, CUMS leads to various long term behavioral, neuro-
chemical, neuroimmune and neuroendocrine alterations that
resemble to those observed in patients with depression (Cryan and
Holmes, 2005).
Clinical reports suggest that obesity and other metabolic disor-
ders are frequently observed among the individuals seeking treat-
ment for mood disorders (McElroy et al., 2004). Increased visceralnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nisms associated with increased cardiometabolic risk may
contribute to the development of mood disorders such as depres-
sion (Vogelzangs et al., 2010). The patients with metabolic syn-
drome or insulin resistance syndrome experience a signiﬁcantly
elevated risk of developing depression (Almeida et al., 2009).
Pioglitazone (PGZ),a well established drug known as peroxi-
some proliferator-activated receptor gamma (PPAR-g) agonist
belonging to thiozolidinodienes (TZDs) class regulates lipid meta-
bolism, exerts potent central and peripheral anti-
neuroinﬂammatory action and possesses neuroprotective effect
(Wozniak et al., 1993; Zhao et al., 2006; Garcia-Bueno et al., 2010;
Heneka and Landreth, 2011). Several clinical and pre-clinical
studies reported TZDs as superior treatments for neurological and
psychiatric conditions including autism (Boris et al., 2007), Alz-
heimer’s disease (Miller et al., 2011), multiple sclerosis (Kaiser et al.,
2009) andMDD (Kemp et al., 2012). Insulin resistance and impaired
glucose tolerance has been observed at higher frequency in
depression (Almeida et al., 2009). A bidirectional relation between
mood disorders and metabolic disturbances is well evident from
the literature (Barry et al., 2009). Rosgan et al. (2002) documented
that treatment of insulin resistance improves depressive
symptoms.
Pioglitazone is well known drug in the treatment of insulin
resistance or altered plasma glucose. Considering the “insulin
resistance or altered plasma glucose” as important pathogenic link
for depression associated with obesity, the present study was
designed to investigate the effect of pioglitazone on CUMS induced




Behavioral experiments were conducted using male Swiss al-
bino mice (20e25 g) that were procured from Hissar Agricultural
University, Hissar, India (Reg. No. 417/01/a/CPCSEA). The animals
were housed under standard laboratory conditions (temperature
22 ± 2 C and room humidity 60 ± 10%) and maintained on 12:12 h
light/dark cycle and had free access to food and water. In India,
Committee for the Purpose of Control and Supervision of Experi-
ments on Animals (CPCSEA) is established under “Prevention of
Cruelty to Animals Act 1960”. CPCSEA has a representative body at
institute level named as Institutional Animal Ethics Committee
(IAEC). The experimental procedures performed on animals were in
compliance with the protocol approved by IAEC of Birla Institute of
Technology & Science, Pilani, India (Protocol No. IAEC/RES/18/09).
2.2. Schedule for drug administration and behavioral tests
Animals were fed with high fat diet (HFD) for 14 weeks, pre-
pared according to Srinivasan et al. (2005). Pioglitazone and esci-
talopram was obtained from Aarti Drugs Limited (Tarapur, India)
and Ranbaxy Laboratories Limited (Gurgaon, India) respectively, asTable 1
Schematic representation of study protocol.





PGZ (30 mg/kg p.o.)/ESC
(10 mg/kg p.o.)/vehicle
(10 ml/kg p.o.)





scorea generous gift sample. The diagnostic kits for estimation of plasma
glucose, total cholesterol, triglycerides and total proteins were
purchased from Spinreact, Girona, Spain. Pioglitazone was pre-
pared as a suspension in 0.25% sodium carboxyl methyl cellulose
(CMC) freshly every day. Pioglitazone was administered by oral
gavage (p.o.) daily from day 14e28 of the CUMS procedure
(Table 1). The dose of pioglitazone (30 mg/kg p.o.) was selected
according to the earlier studies (Kashani et al., 2013; Sato et al.,
2011; Kubota et al., 2006).
2.3. Experimental design
Sixty mice were randomized based on body weight and divided
into ten different groups (n¼ 6/group). Group I consisted of Normal
pellet diet (NPD) mice receiving vehicle by gavage (10 ml/kg p.o.),
group II comprised of NPD þ pioglitazone (30 mg/kg p.o.), group III
comprised of NPD þ CUMS control, group IV consisted of
NPD þ CUMS þ pioglitazone (30 mg/kg p.o.), group V consisted of
NPDþ CUMSþ escitalopram (10mg/kg p.o.), group VI comprised of
HFD control, group VII consisted of HFD þ pioglitazone (30 mg/kg
p.o.), group VIII comprised of HFD þ CUMS control, group IX con-
sisted of HFD þ CUMS þ pioglitazone (30 mg/kg p.o.) and group X
comprised of HFDþ CUMSþ escitalopram (10 mg/kg p.o.). Initially,
for oneweek period, animals were only subjected to different stress
procedures. From day 8th to 28th along with stress, animals of
group II, IV, VII and IX received pioglitazone (30 mg/kg p.o.), group
V and X received escitalopram (10 mg/kg p.o.) using oral gavage
daily once, whereas, group I, III, VI and VIII were administered with
vehicle orally through oral gavage as a suspension of 0.25% sodium
carboxyl methyl cellulose (CMC) (Table 1).
2.4. Chronic unpredictable mild stress procedure
The CUMS was performed as described earlier (Ducottet et al.,
2003). Brieﬂy, the CUMS protocol consisted of the sequential
application of a variety of mild stressors. These stressors were
randomly scheduled over oneweek period as shown in Table 2, and
repeated throughout the 4 week experiment. Non-stressed animals
were left undisturbed in their home cages except during house-
keeping procedures such as cage cleaning.
2.5. Behavioral tests battery
2.5.1. Sucrose preference test
The test was performed as described earlier (Casarotto and
Andreatini, 2007) with minor modiﬁcations. Brieﬂy, before the
test, mice were trained to adapt to sucrose solution (1%, w/v), two
bottles of sucrose solution were placed in each cage for 24 h and
then one bottle of sucrose solution was replaced with water for
24 h. After the adaptation, micewere deprived of water and food for
24 h. Sucrose preference test was conducted at 9:30 a.m. in which
micewere housed in individual cages andwere free to access to two
bottles containing 100 ml of sucrose solution (1% w/v) and 100 ml
of water, respectively. After 24 h, the volumes of consumed sucrose
solution and water were recorded and the sucrose preference was39th day 40th day onwards
Collection of blood Biochemical assessment
35 36 37 Plasma glucose, plasma total cholesterol, plasma triglycerides,
plasma total proteinsor FST TST EPM
Table 2
Schedule for chronic unpredictable mild stress (CUMS) procedure.
Sr. No. Day Type of stress Time
1. Monday Food and water deprivation 24 h (9 a.m.e9 a.m.)
2. Tuesday Empty bottle 1 h (9 a.m.e10 a.m.)
Foreign object (eg. marbles) 24 h (9 a.m.e9 a.m.)
3. Wednesday Overnight illumination 10 h (8 p.m.e6 a.m.)
Forced Swimming 1 h (4 min/animal) (9 a.m.e10 a.m.)
4. Thursday Cage tilt 5 h (12 p.m.e5 p.m.)
Restraint 1 h (10 a.m.e11 a.m.)
5. Friday Food deprivation 12 h (9 a.m.e9 p.m.)
Soiled cage (with water) 12 h (9 p.m.e9 a.m.)
6. Saturday Water deprivation 12 h (10 a.m.e10 p.m.)
Overnight illumination 12 h (7 p.m.e7 a.m.)
7. Sunday Empty bottles 2 h (10 a.m.e12 a.m.)
Cage tilt 5 h (12 a.m.e5 p.m.)
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% Sucrose preference ¼ [Sucrose consumption (ml)/
Water þ Sucrose consumption (ml)]  100
2.5.2. Spontaneous locomotor activity test
The spontaneous locomotor activity of HFD obese mice sub-
jected to CUMS was measured by using actophotometer (Boissier
and Simon, 1965; Engeland et al., 2003) (INCO, India) which con-
sisted of a square arena (30  30 cm) and walls along with pho-
tocells just above the level of ﬂoor. On the day of experiment, before
beginning of the tests, photocells were checked properly. As the
beam of light is cut by the movement of animal the reading is
automatically recorded by counter and displayed on the screen.
Mice from all the respective groupswere gently placed in the center
of the box individually. After initial 1 min of acclimatization period,
the locomotor activity scorewas recorded digitally for next 4min in
a dimly lit room. After each test, the ﬂoor was cleaned thoroughly
with 75% alcohol solution to eliminate possible bias due to odors
left by previous mice.
2.5.3. Forced swim test (FST)
FST was performed as described previously (Porsolt et al., 1977)
with slight modiﬁcation. Brieﬂy, the mice were individually forced
to swim in a 25  12  25 cm (L  B  H) ﬁlled with water
(23 ± 2 C) up to a height of 15 cm. Animals were allowed to swim
for 15 min as training period 24 h before commencement of the
test. On the test day, after the initial 2 min of vigorous activity, mice
were observed for immobility for next 4 min. An animal was
considered to be immobile whenever it remained ﬂoating passively
in the water in a slightly hunched but upright position, its nose
above the water surface. This immobile posture reﬂects a state of
behavioral despair or helplessness (Santiago et al., 2010).
2.5.4. Tail suspension test (TST)
The TST is another well established animal model for screening
antidepressants. The method was adopted from previous studies
(Steru et al., 1985; Yamawaki et al., 2012). Brieﬂy, mice were sus-
pended by the bands and hung from a hook mounted 50 cm above
the ﬂoor for 6 min. The time that the mice spent immobile during
the 6 min of the testing period was measured. Immobility was
considered as lack of all movement except for whisker movement
and respiration.
2.5.5. Elevated plus maze (EPM)
The elevated plus maze was performed by the methodmentioned earlier (Adeyemi et al., 2006). Brieﬂy, it consisted of two
open and two closed arms (all arms: 20  4  12 cm) made of
wooden blocks elevated at a height of 25 cm from ﬂoor, which was
lighten with 60 W bulb through a height of 100 cm. Each mouse
was placed in the central square (5 cm  5 cm) facing an open arm
and allowed to explore the maze for 5 min of test period. The
parameter measured was time spent in open arm and number of
entries in open arm. The maze was cleaned with dilute alcohol in
between two test sessions to get rid of residual odor.2.6. Biochemical parameters
2.6.1. Estimation of plasma glucose, total cholesterol, triglycerides
and total proteins
Two days post behavioral tests, animals were bleeded by sinus
retro-orbital route for collection of plasma in a tube containing
10 ml of heparin solution and centrifuged at 10,000 rpm for 15 min.
Estimation of plasma glucose (Trinder, 1969), total cholesterol
(Meittini et al., 1978), triglycerides (Buccolo and David, 1973) and
total proteins (Koller, 1984) was done by using commercially
available kits (Spineract).2.7. Statistical analysis
Data were analyzed using Graph Pad PRISM software version
2.01 (GraphPad Software, La Jolla, USA). One speciﬁc group of mice
was assigned to one speciﬁc drug treatment condition. All the
values are expressed as mean ± standard error of the mean (S.E.M.).
The signiﬁcance of differences between groups for behavioral and
biochemical assays were analyzed using two-way analysis of vari-
ance (ANOVA) followed by post hoc Bonferroni test. For statistical
analysis p < 0.05 was considered statistically signiﬁcant.3. Results
3.1. Behavioral assessments
3.1.1. Effect of pioglitazone treatment on body weight of HFD obese
mice subjected to CUMS
The effect of pioglitazone on body weight is shown Fig. 1. HFD
control group showed signiﬁcantly (p < 0.01) higher body weight
compared to NPD control animals. HFD mice exposed to CUMS
showed signiﬁcant weight reduction compared to HFD control
group (p < 0.01). Repeated treatment with pioglitazone (30 mg/kg
p.o.) and standard reference drug escitalopram (10 mg/kg p.o.)
signiﬁcantly [F (9, 50) ¼ 708.7, p < 0.01] reversed the reduced
weight in obese mice subjected to CUMS.
Fig. 1. Effect of PGZ (30 mg/kg p.o.) treatment on the body weight of obese mice
subjected to CUMS. All the values are expressed as mean ± S.E.M., aap < 0.01 as
compared to NPD control group, ccp < 0.01 as compared to NPD group treated with
PGZ, ddp < 0.01 as compared to NPD þ CUMS group, eep < 0.01 as compared to
NPD þ CUMS mice treated with PGZ (30 mg/kg p.o.), ffP < 0.01 as compared to
NPD þ CUMS mice treated with ESC (10 mg/kg p.o.), n ¼ 6/group.
Fig. 3. Effect of PGZ (30 mg/kg p.o.) treatment on the locomotor activity score in obese
mice subjected to CUMS. All the values are expressed as mean ± S.E.M., aap < 0.01 as
compared to NPD control group, bp < 0.05 as compared to NPD þ CUMS group,
##p < 0.01 as compared to HFD control group, **p < 0.01 as compared to HFD þ CUMS
group, n ¼ 6/group.
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preference in HFD obese mice subjected to CUMS
HFD control animals showed signiﬁcantly (p < 0.01) reduced
sucrose consumption compared to normal control animals (Fig. 2).
HFD þ CUMS control group exhibited signiﬁcantly (p < 0.01)
decreased sucrose consumption as compared to HFD control ani-
mals. Chronic treatment with pioglitazone (30 mg/kg p.o.) and
standard escitalopram (10 mg/kg p.o.) showed signiﬁcantly [F (9,
50)¼ 14.18, p < 0.01] increased sucrose consumption in obese mice
subjected to CUMS.3.1.3. Effect of pioglitazone treatment on spontaneous locomotor
activity in HFD obese mice subjected to CUMS
The locomotor activity in normal, HFD obese and HFD þ CUMS
animals is shown in Fig. 3. No alteration was observed in the lo-
comotor activity between the normal control and HFD control mice.
However, obese mice subjected to CUMS showed signiﬁcantly
(p < 0.01) decreased locomotor activity as compared to HFD control
group. Chronic treatment with pioglitazone (30 mg/kg p.o.) and
standard drug escitalopram (10 mg/kg p.o.) signiﬁcantly [F (9,
50) ¼ 9.35, p < 0.01] reversed the CUMS induced reduced loco-
motor activity in obese mice.Fig. 2. Effect of PGZ (30 mg/kg p.o.) treatment on the percent sucrose preference in
HFD þ CUMS mice. All the values are expressed as mean ± S.E.M., aap < 0.01 as
compared to NPD control group, bbp < 0.01 as compared to NPD þ CUMS group,
#p < 0.05; ##p < 0.01 as compared to HFD control group, **p < 0.01 as compared to
HFD þ CUMS group, n ¼ 6/group.3.1.4. Effect of pioglitazone treatment on immobility time in FST in
HFD obese mice subjected to CUMS
Fig. 4 shows the effect of repetitive treatment on immobility
time in FST in stressed obese mice. HFD control animals exhibited
signiﬁcantly (p < 0.05) increased immobility time in FST compared
to normal control animals. CUMS signiﬁcantly (p < 0.05) increased
the immobility time in obese in FST compared to obese control
group. Pioglitazone (30 mg/kg p.o.) and standard escitalopram
(10mg/kg p.o.) signiﬁcantly [F (9, 50)¼ 18.56, p < 0.01) reduced the
immobility time in obese mice subjected to CUMS in FST.3.1.5. Effect of pioglitazone treatment on immobility time in TST in
HFD obese mice subjected to CUMS
The effect of pioglitazone treatment on immobility time in TST is
shown in Fig. 5. HFD control animals exhibited signiﬁcant (p < 0.05)
higher immobility time compared to normal control group in TST.
In obese animals CUMS signiﬁcantly (p < 0.05) increased duration
of immobility as compared to HFD control group. Chronic treat-
ment with pioglitazone (30 mg/kg p.o.) and standard reference
drug escitalopram (10 mg/kg p.o.) signiﬁcantly [F (9, 50) ¼ 9.77,
p < 0.01] reduced the immobility time in obese animals subjected
to CUMS compared to HFD þ CUMS control group in TST.Fig. 4. Effect of PGZ (30 mg/kg p.o.) treatment on the immobility time in FST in obese
mice subjected to CUMS. All the values are expressed as mean ± S.E.M., ap < 0.05 as
compared to NPD control group, bbp < 0.01 as compared to NPD þ CUMS group,
#p < 0.05; ##p < 0.01 as compared to HFD control group, **p < 0.01 as compared to
HFD þ CUMS group, n ¼ 6/group.
Fig. 5. Effect of PGZ (30 mg/kg p.o.) treatment on the immobility time in TST in obese
mice subjected to CUMS. All the values are expressed as mean ± S.E.M., ap < 0.05 as
compared to NPD control group, bbp < 0.01 as compared to NPD þ CUMS group,
#p < 0.05 as compared to HFD control group, **p < 0.01 as compared to HFD þ CUMS
group, n ¼ 6/group.
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subjected to CUMS
The effect of pioglitazone treatment on EPM is represented in
Table 3. HFD group showed signiﬁcantly (p < 0.01) reduced percent
time spent in open arm as compared to normal control animals.
HFD þ CUMS animals showed signiﬁcantly (p < 0.01) decreased
time in open arm as compared to HFD control animals. However,
percent open arm entries were not signiﬁcantly altered in HFD and
HFDþ CUMS animals compared to normal and HFD control groups,
respectively with pioglitazone treatment. Repetitive treatment
with pioglitazone (30 mg/kg p.o.) and standard escitalopram
(10 mg/kg p.o.) showed signiﬁcant [F (9, 50) ¼ 13.11, p < 0.01]
increased percent time in obese animals subjected to CUMS as
compared to HFD þ CUMS control group. Pioglitazone (30 mg/kg
p.o.) and standard escitalopram (10 mg/kg p.o.) did not showed
signiﬁcant effect on the percent open arm entries in obese mice
subjected to CUMS.
3.2. Biochemical analysis
3.2.1. Effect of pioglitazone treatment on plasma glucose, total
cholesterol, triglycerides and total proteins in HFD obese mice
subjected to CUMS
The effect of pioglitazone treatment on plasma biochemical
parameters is shown in Table 4. HFD control animals showed sig-
niﬁcant (p < 0.01) increased levels of plasma glucose, total
cholesterol, triglycerides and total proteins as compared to normal
control animals. Obese mice subjected to CUMS showed signiﬁcant
(p < 0.05) increased plasma glucose as compared to HFD control
animals, whereas no signiﬁcant alterations in plasma total choles-
terol, triglycerides and total proteins were observed in obese mice
subjected to CUMS compared to HFD control group. Chronic
treatment with pioglitazone (30 mg/kg p.o.) and standard drug
escitalopram (10 mg/kg p.o.) signiﬁcantly reduced the elevated
plasma glucose [F (9, 50) ¼ 9.89, p < 0.01], total cholesterol [F (9,
50) ¼ 24.14, p < 0.05], triglycerides [F (9, 50) ¼ 19.42, p < 0.05] and
total proteins [F (9, 50) ¼ 5.46, p < 0.01] as compared to HFD and
HFD þ CUMS groups, respectively.
4. Discussion
Several meta-analysis studies demonstrated that obesity is
associatedwith increased risk of developing depression (Zhao et al.,
2009). The chronic consumption of HFD risks the anxiety and
depressive-like behavior, heightens the HPA axis response to stressand leads to several biochemical modiﬁcations (Sharma and Fulton,
2012). The use of animal model for human mental disorder, despite
of their oblivious limitation have proved to be of great value in the
pre-clinical analysis for experimental validation of psychopha-
rmacological assessment. It is reported that, chronic stress plays an
important role in the onset and relapse of depression (Lee et al.,
2002). CUMS induced depression is probably the most popular
and suitable model to study depressive behavior in rodents as it
possesses higher face, construct and predictive validities, reﬂecting
the similarities in the pathogenic and behavioral alteration in hu-
man and animal depression. CUMS model aims to simulate severe
depressive-like condition that is developed gradually as those are
generally observed in depression patients (Luo et al., 2008). How-
ever, CUMS model provide insight but obviously cannot recapitu-
late the complex pathophysiology of major depressive disorder
(Willner et al., 1992). Stress leads to increases triglycerides and free
fatty acids. These abnormal lipid levels inhibit the release of insulin
in response to glucose that further worsens the insulin resistance
(Borchard, 2001). Stress also plays a crucial role in the development
of systemic inﬂammation that are considered as metabolic syn-
drome by elevating the levels of pro-inﬂammatory cytokines such
as tumor necrosis factor-alpha (TNF-a), interlukin-6 (IL-6) (Wisse,
2004). These inﬂammatory markers are proportional to the de-
gree of obesity and insulin resistance. Evidence supports the role of
these inﬂammatory markers in development of diabetes (Pradhan
et al., 2001). Earlier research has made a clear indication of the
relationship between stress response, visceral fat, insulin resistance
and HPA axis dysregulation (Rosmond et al., 1998). It has been re-
ported that psychosocial stress in primates leads to development of
several abnormal conditions such as elevated corticosterone, in-
sulin resistance, dyslipidemia, hypertension and coronary athero-
sclerosis (Jayo et al., 1993). In humans stress causes abnormal
cortisol secretion that further causes metabolic disorder such as
insulin resistance, diabetes and psychological diseases such as
depression, anxiety (Rosmond and Bjorntorp, 2000; Raikkonen
et al., 1994).
PPARg receptors are present in various regions of the brain viz.
hippocampus, striatum, frontal cortex and hypothalamus (Drew
et al., 2006) and expressed on immune cells (Heneka et al., 2007).
Several clinical (Kemp et al., 2006, 2012) and pre-clinical studies
(Eissa et al., 2009; Sadaghiani et al., 2011) have described the
antidepressant-like effects of PPARg agonists rosiglitazone and
pioglitazone.
Anhedonia indicates lack of pleasure or interest which is one of
the major hallmark of human depressive symptoms and in animals
this is evidenced through reduced preference for sucrose (Willner
et al., 1987; Strekalova et al., 2006). Further, high predictive val-
idity models (Cryan and Slattery, 2007; Cryan et al., 2005) like FST
and TSTwere performed. In order to avoid the false positive results,
locomotor activity score was measured and no alterations were
observed in the basal locomotor activity between normal animals
and HFD control animals. EPM is widely used for screening anti-
anxiety agents (Hogg, 1996) where it reﬂects the psychomotor
and emotional aspects in rodents which correlate with uncondi-
tioned anxiety. Anxiolytics elevates the frequency of entries and
time spent in open arms in EPM (Dawson and Tricklebank, 1995).
Overall, the result of behavioral studies examines the
antidepressive-like effect of pioglitazone by improving sucrose
consumption, reducing immobility time in FST and TST, increasing
percent open arm time in EPM on CUMS induced depression in
obese mice.
Furthermore, in the biochemical assessments, plasma glucose,
total cholesterol, triglycerides and total proteins were estimated in
obese mice subjected to CUMS. Plasma glucose is one of the most
important biochemical assessments as “insulin resistance” is
Table 4
Effect of PGZ treatment on plasma glucose, total cholesterol, triglycerides and total proteins.
Groups Plasma glucose (mg/dl) Plasma total cholesterol (mg/dl) Plasma triglycerides (mg/dl) Plasma total proteins (g/dl)
NPD control 109.37 ± 4.39 70.09 ± 2.59 96.41 ± 5.27 18.61 ± 1.74
NPD þ PGZ (30 mg/kg p.o.) 112.82 ± 4.40 69.18 ± 3.32 97.31 ± 4.27 19.75 ± 1.48
NPD þ CUMS control 120.60 ± 5.91 64.43 ± 6.98 84.49 ± 4.96 22.82 ± 1.02
NPD þ CUMS þ PGZ (30 mg/kg p.o.) 110.79 ± 5.35 62.22 ± 5.70 73.63 ± 4.45 22.75 ± 1.43
NPD þ CUMS þ ESC (10 mg/kg p.o.) 105.89 ± 5.49 63.79 ± 4.52 79.56 ± 4.01 21.91 ± 2.25
HFD control 139.43 ± 8.43aa 136.01 ± 5.37aa 158.64 ± 5.56aa 27.04 ± 2.15aa
HFD þ PGZ (30 mg/kg p.o.) 119.86 ± 5.10 90.14 ± 6.68## 114.60 ± 6.35## 19.17 ± 1.14#
HFD þ CUMS control 162.45 ± 5.29# 116.39 ± 6.18 137.42 ± 10.42 31.87 ± 2.09
HFD þ CUMS þ PGZ (30 mg/kg p.o.) 131.12 ± 4.84** 94.21 ± 3.05* 111.96 ± 7.52* 23.08 ± 1.30**
HFD þ CUMS þ ESC (10 mg/kg p.o.) 134.47 ± 5.20** 98.70 ± 4.84 118.65 ± 4.11* 22.67 ± 1.81**
All the values are expressed as mean ± S.E.M., aap < 0.01 as compared to NPD control group, #p < 0.05; ##p < 0.01 as compared to HFD control group, *p < 0.05; **p < 0.01 as
compared to HFD þ CUMS group, n ¼ 6/group.
PGZ; pioglitazone, ESC; escitalopram, NPD; normal pellet chow, HFD; high fat diet, CUMS; chronic unpredictable mild stress.
Table 3
Effect of PGZ treatment on elevated plus maze test in HFD obese mice subjected to CUMS.
Groups % Open arm entries % Time in open arm (s)
NPD control 42.83 ± 4.28 19.78 ± 1.26
NPD þ PGZ (30 mg/kg p.o.) 41.94 ± 3.74 18.61 ± 0.78
NPD þ CUMS control 23.86 ± 3.37aa 10.94 ± 1.32aa
NPD þ CUMS þ PGZ (30 mg/kg p.o.) 48.59 ± 3.08bb 18.28 ± 0.72bb
NPD þ CUMS þ ESC (10 mg/kg p.o.) 45.25 ± 3.30bb 19.06 ± 1.66bb
HFD control 32.65 ± 4.40 13.39 ± 0.72aa
HFD þ PGZ (30 mg/kg p.o.) 38.91 ± 5.24 17.11 ± 1.07##
HFD þ CUMS control 27.67 ± 3.35 6.78 ± 0.92##
HFD þ CUMS þ PGZ (30 mg/kg p.o.) 32.61 ± 3.26 13.89 ± 1.56**
HFD þ CUMS þ ESC (10 mg/kg p.o.) 29.78 ± 2.16 13.44 ± 1.09**
All the values are expressed as mean ± S.E.M., aap < 0.01 as compared to NPD control group, bbp < 0.01 as compared to NPD þ CUMS control,
##p < 0.01 as compared to HFD control group, **p < 0.01 as compared to HFD þ CUMS control group, n ¼ 6/group.
PGZ; pioglitazone, ESC; escitalopram, NPD; normal pellet chow, HFD; high fat diet, CUMS; chronic unpredictable mild stress.
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resistance” due to excess cortisol release in the circulation owing to
dysregulation of hypothalamus pituitary adrenal (HPA) axis, as
observed in depressed and obese subjects (Brown et al., 2004).
Obesity is well known metabolic disorder in which “insulin resis-
tance” holds the key and is characterized by dysregulation of lipids
(Kahn and Flier, 2000; Lee et al., 2013). In the earlier reports it is
well understood that, an association of dyslipidemia and obesity
with the individuals reﬂecting more depressive and anxiety-like
behavior (Van Reedt Dortland et al., 2010). Reduced level of total
proteins in depression (Maes et al., 1995) whereas, unclear inﬂu-
ence of total protein synthesis in obesity is well discussed previ-
ously (Anderson et al., 2008). Our study showed elevated plasma
glucose, total cholesterol, triglycerides and total proteins in HFD
obese mice subjected to CUMS. Pioglitazone reversed these
biochemical alterations through agonistic action at PPAR-gamma
receptor thereby increasing the peripheral glucose utilization.
Moreover, we claim that “altered glucose or insulin resistance” as
major hallmark for depressive behavior associated with obesity and
treatment of the “altered glucose or insulin resistance” ameliorates
these co-morbid disorders.
The results of biochemical assessments showed similarities with
the earlier reports suggesting improved insulin sensitization and
lipid lowering properties of pioglitazone by regulating a tran-
scription factor responsible for glucose and fat metabolism
(Srinivasan et al., 2004). From a mechanistic standpoint, improved
depression severity with repetitive pioglitazone treatment may
occur due to decreased in visceral adiposity and inﬂammation, and
improved insulin sensitivity. Pioglitazone is reported to cross the
blood brain barrier (Maeshiba et al., 1997) that may mediate
improved depressive behavior by increasing neuronal survival
(Fuenzalida et al., 2007), increasing glial uptake of excitotoxicmolecules (Romera et al., 2007), or modulating Calcium dependent
pathways in the brain (Pancani et al., 2009). A better understanding
of the mechanisms linking insulin resistance with depression could
provide therapeutic strategies with novel mechanisms. Although
the exact mechanism(s) of pioglitazone is not well understood, it is
known to decrease free fatty acid levels and insulin gene tran-
scription, to remodel lipid distribution and to improve glucose
disposal in insulin-resistant individuals (Schinner et al., 2009). At
the molecular level, it acts as ligands for PPARg, a nuclear receptor
of the NR1C family, expressed predominantly in adipose tissue. In
addition to improving glucose disposal, pioglitazone favorably
altered lipid distribution in the body. Deposition of fat in the non-
adipose tissue such as liver and muscle has been implicated in the
development of insulin resistance. The PPARg agonist pioglitazone
is known to improve lipid distribution, insulin sensitivity and to
suppress hepatic glucose production (Vikram et al., 2010). The
plasma glucose and lipid proﬁle was reduced by pioglitazone in our
ﬁndings in obese animals exposed to chronic stress. This was our
preliminary investigation suggesting that as pioglitazone has abil-
ity to cross BBB, future research exploring this mechanism could
turn out very crucial. Also, pioglitazone has ability to improve pe-
ripheral insulin sensitivity by controlling the blood glucose and
lipid distribution. Therefore, studying and exploring the mecha-
nisms of pioglitazone including both central action and peripheral
action could be very interesting area of for future research in the
ﬁeld of metabolic brain disorders such as co-morbid depression,
anxiety associated with obesity.5. Conclusion
In conclusion, in the present study chronic treatment with
PPARg agonist, pioglitazone reversed the CUMS induced behavioral
Y. Kurhe, R. Mahesh / Neurobiology of Stress 3 (2016) 114e121120and biochemical changes in obese mice, thus exhibiting
antidepressive-like effect. The plasma glucose level indicates that
the “altered plasma glucose or insulin resistance”, to play a crucial
role in such co-morbid disorders and pioglitazone through activa-
tion of PPARg receptors alleviated the “altered plasma glucose or
insulin resistance” and exhibited antidepressant-like effect. How-
ever, these are only the preliminary ﬁndings and hence, further
studies dealing with the role of pioglitazone with respect to mo-
lecular mechanisms including brain derived neurotrophic factor
(BDNF), corticosterone levels, mRNA expression in cortex and
hippocampus in depression associated with obesity will shade light
on the mechanism aspects.
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